Total plasma protein effect on tacrolimus elimination in kidney transplant patients - Population pharmacokinetic approach

European Journal of Pharmaceutical Sciences

Volumn 52, Issue 1, 2014, Pages 34-40

  Golubović, Bojana ^a   Vučićević, Katarina ^a   Radivojević, Dragana ^a   Kovačević, Sandra Vezmar ^a   Prostran, Milica ^a   Miljković, Branislava ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Kidney transplantation; Plasma proteins; Population pharmacokinetics; Tacrolimus; Therapeutic monitoring

Indexed keywords

ASPARTATE AMINOTRANSFERASE; PLASMA PROTEIN; TACROLIMUS;

ARTICLE; BODY WEIGHT; CORRELATION ANALYSIS; DRUG CLEARANCE; DRUG ELIMINATION; FEMALE; HEMATOCRIT; HUMAN; HUMAN TISSUE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

KIDNEY TRANSPLANTATION; PLASMA PROTEINS; POPULATION PHARMACOKINETICS; TACROLIMUS; THERAPEUTIC MONITORING;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; BLOOD PROTEINS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MYCOPHENOLIC ACID; TACROLIMUS; YOUNG ADULT;

EID: 84887585346     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2013.10.008     Document Type: Article

References (50)

1. D. Anglicheau, M. Flamant, M.H. Schlageter, F. Martinez, B. Cassinat, P. Beaune, C. Legendre, and E. Thervet Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation Nephrol. Dial Transplant 18 2003 2409 2414 (Pubitemid 37336834)
2. M. Antignac, J.S. Hulot, E. Boleslawski, L. Hannoun, Y. Touitou, R. Farinotti, P. Lechat, and S. Urien Population pharmacokinetics of tacrolimus in full liver transplant patients: modelling of the post-operative clearance Eur. J. Clin. Pharmacol. 61 2005 409 416 (Pubitemid 41569318)
3. M. Antignac, B. Barrou, R. Farinotti, P. Lechat, and S. Urien Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients Br. J. Clin. Pharmacol. 64 2007 750 757 (Pubitemid 350222052)
4. M. Antignac, C. Fernandez, B. Barrou, M. Roca, J.L. Favrat, S. Urien, and R. Farinotti Prediction tacrolimus blood levels based on the Bayesian method in adult kidney transplant patients Eur. J. Drug Metab. Pharmacokinet. 36 2011 25 33
5. ARCHITECT System. Tacrolimus package insert. Abbott Laboratories, 2009.
6. J. Barett Population pharmacokinetics R. Schoenwald, Pharmacokinetics in Drug Discovery and Development 2002 CRC Press Boca Raton 315 356
7. M. Bergstrand, A.C. Hooker, J.E. Wallin, and M.O. Karlsson Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models Aaps J. 13 2011 143 151
8. P. Bonate Pharmacokinetic-Pharmacodynamic Modeling and Simulation 2006 Springer New York
9. B.P. Booth, and J.V. Gobburu Considerations in analyzing single-trough concentrations using mixed-effects modeling J. Clin. Pharmacol. 43 2003 1307 1315 (Pubitemid 37433303)
10. A.M. Borobia, I. Romero, C. Jimenez, F. Gil, E. Ramirez, R. De Gracia, F. Escuin, E. Gonzalez, and A.J. Sansuan Trough tacrolimus concentrations in the first week after kidney transplantation are related to acute rejection Ther. Drug Monit. 31 2009 436 442
11. L.C. Borra, J.I. Roodnat, J.A. Kal, R.A. Mathot, W. Weimar, and T. van Gelder High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation Nephrol. Dial Transplant 25 2010 2757 2763
12. L.J. Bowman, and D.C. Brennan The role of tacrolimus in renal transplantation Expert Opin. Pharmacother. 9 2008 635 643 (Pubitemid 351425390)
13. M.E. Burton, L.M. Shaw, J.J. Schentag, and W.E. Evans Applied Pharmacokinetics and Pharmacodynamics: Principles of Therapeutic Drug Monitoring fourth ed. 2005 Lippincot Williams & Wilkins
14. T. Fournier, N.N. Medjoubi, and D. Porquet Alpha-1-acid glycoprotein Biochim. Biophys. Acta 1482 2000 157 171
15. L.W. Gaber, L.W. Moore, L. Reed, W. Russell, R. Alloway, D. Hathaway, M.H. Shokouh-Amiri, and A.O. Gaber Renal histology with varying FK506 blood levels Transplant Proc. 29 1997 186 (Pubitemid 27125928)
16. M.J. Garcia Sanchez, C. Manzanares, D. Santos-Buelga, A. Blazquez, J. Manzanares, P. Urruzuno, and E. Medina Covariate effects on the apparent clearance of tacrolimus in paediatric liver transplant patients undergoing conversion therapy Clin. Pharmacokinet. 40 2001 63 71 (Pubitemid 32182114)
17. N. Han, H.Y. Yun, J.Y. Hong, I.W. Kim, E. Ji, S.H. Hong, Y.S. Kim, J. Ha, W.G. Shin, and J.M. Oh Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients Eur. J. Clin. Pharmacol. 69 2013 53 63
18. F. Harrel Regression Modeling Strategies 2001 Springer New York
19. D.A. Hesselink, H. Ngyuen, M. Wabbijn, P.J. Gregoor, E.W. Steyerberg, I.C. van Riemsdijk, W. Weimar, and T. van Gelder Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids Br. J. Clin. Pharmacol. 56 2003 327 330 (Pubitemid 37059661)
20. A.C. Hooker, C.E. Staatz, and M.O. Karlsson Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method Pharm. Res. 24 2007 2187 2197 (Pubitemid 350060706)
21. Z.H. Israili, and P.G. Dayton Human alpha-1-glycoprotein and its interactions with drugs Drug Metab. Rev. 33 2001 161 235 (Pubitemid 32703255)
22. A.B. Jain, S. Todo, J.J. Fung, R. Venkataramanan, R. Day, J. Bryant, K.M. Abu-Elmagd, M. Alessiani, S. Takaya, and A. Tzakis Correlation of rejection episodes with FK 506 dosage, FK 506 level, and steroids following primary orthotopic liver transplant Transplant Proc. 23 1991 3023 3025
23. H. Jeong, and W.L. Chiou Role of P-glycoprotein in the hepatic metabolism of tacrolimus Xenobiotica 36 2006 1 13
24. M.O. Karlsson, and R.M. Savic Diagnosing model diagnostics Clin. Pharmacol. Ther. 82 2007 17 20 (Pubitemid 46944205)
25. R.P. Kershner, and W.E. Fitzsimmons Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation Transplantation 62 1996 920 926 (Pubitemid 26360352)
26. I. Koch, R. Weil, R. Wolbold, J. Brockmoller, E. Hustert, O. Burk, A. Nuessler, P. Neuhaus, M. Eichelbaum, U. Zanger, and L. Wojnowski Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA Drug Metab. Dispos. 30 2002 1108 1114
27. D. Li, W. Lu, J.Y. Zhu, J. Gao, Y.Q. Lou, and G.L. Zhang Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients J. Clin. Pharm. Ther. 32 2007 505 515 (Pubitemid 47404287)
28. P.T. Loh, H.X. Lou, Y. Zhao, Y.M. Chin, and A. Vathsala Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients Transplant Proc. 40 2008 1690 1695 (Pubitemid 351853194)
29. I.A. Macphee, S. Fredericks, T. Tai, P. Syrris, N.D. Carter, A. Johnston, L. Goldberg, and D.W. Holt Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement Transplantation 74 2002 1486 1489 (Pubitemid 36014218)
30. S.I. Park, C.R. Felipe, P.G. Pinheiro-Machado, R. Garcia, F.B. Fernandes, D.E. Casarini, H. Tedesco-Silva Jr., and J.O. Medina-Pestana Tacrolimus pharmacokinetic drug interactions: effect of prednisone, mycophenolic acid or sirolimus Fundam. Clin. Pharmacol. 23 2009 137 145
31. J. Parke, N.H. Holford, and B.G. Charles A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models Comput. Methods Programs Biomed. 59 1999 19 29 (Pubitemid 29125558)
32. C. Passey, A.K. Birnbaum, R.C. Brundage, W.S. Oetting, A.K. Israni, and P.A. Jacobson Dosing equation for tacrolimus using genetic variants and clinical factors Br. J. Clin. Pharmacol. 72 2011 948 957
33. J.H. Proost Adaptive control of drug dosage regimens using maximum a posteriori probability Bayesian fitting Int. J. Clin. Pharmacol. Ther. 33 1995 531 536
34. C. Rosso Felipe, T.V. de Sandes, E.L. Sampaio, S.I. Park, H.T. Silva Jr., and J.O. Medina Pestana Clinical impact of polymorphisms of transport proteins and enzymes involved in the metabolism of immunosuppressive drugs Transplant Proc. 41 2009 1441 1455
35. R.M. Savic, and M.O. Karlsson Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions Aaps J. 11 2009 558 569
36. L.B. Sheiner, and S.L. Beal Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data J. Pharmacokinet. Biopharm. 11 1983 303 319 (Pubitemid 14074006)
37. C.E. Staatz, and S.E. Tett Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation Clin Pharmacokinet 43 2004 623 653 (Pubitemid 38981845)
38. C. Staatz, P. Taylor, and S. Tett Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation Nephrol. Dial. Transplant 16 2001 1905 1909 (Pubitemid 32821425)
39. C.E. Staatz, C. Willis, P.J. Taylor, and S.E. Tett Population pharmacokinetics of tacrolimus in adult kidney transplant recipients Clin. Pharmacol. Ther. 72 2002 660 669 (Pubitemid 36021005)
40. Summary of Product Characteristics. Last update on the eMC: 18/09/2012. < http://www.medicines.org.uk/EMC/history/11102/SPC/Prograf+0. 5mg%2c+1mg%2c+5mg+Har >.
41. N.A. Undre, and A. Schafer Factors affecting the pharmacokinetics of tacrolimus in the first year after renal transplantation. European Tacrolimus Multicentre Renal Study Group Transplant Proc. 30 1998 1261 1263 (Pubitemid 28309564)
42. J.L. Vannice, J.M. Taylor, and G.M. Ringold Glucocorticoid-mediated induction of alpha 1-acid glycoprotein: evidence for hormone-regulated RNA processing Proc. Natl. Acad. Sci. USA 81 1984 4241 4245 (Pubitemid 14052419)
43. R. Venkataramanan, A. Swaminathan, T. Prasad, A. Jain, S. Zuckerman, V. Warty, J. McMichael, J. Lever, G. Burckart, and T. Starzl Clinical pharmacokinetics of tacrolimus Clin. Pharmacokinet. 29 1995 404 430 (Pubitemid 26004179)
44. R. Venkataramanan, L.M. Shaw, L. Sarkozi, R. Mullins, J. Pirsch, G. MacFarlane, D. Scheller, D. Ersfeld, M. Frick, W.E. Fitzsimmons, M. Virji, A. Jain, K.L. Brayman, and A. Shaked Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients J. Clin. Pharmacol. 41 2001 542 551 (Pubitemid 32381872)
45. K. Vucicevic, B. Miljkovic, M. Pokrajac, M. Prostran, Z. Martinovic, and I. Grabnar The influence of drug-drug interaction and patients' characteristics on valproic acid's clearance in adults with epilepsy using nonlinear mixed effects modeling Eur. J. Pharm. Sci.: Off. J. Eur. Fed. Pharm. Sci. 38 2009 512 518
46. V. Warty, R. Venkataramanan, P. Zendehrouh, T. McKaveney, J. Chao, S. Todo, and T. Starzl Distribution of FK 506 in plasma lipoproteins in transplant patients Transplant Proc. 23 1991 954 955
47. H. Zahir, G. McCaughan, M. Gleeson, R.A. Nand, and A.J. McLachlan Factors affecting variability in distribution of tacrolimus in liver transplant recipients Br. J. Clin. Pharmacol. 57 2004 298 309 (Pubitemid 38296993)
48. H. Zahir, A.J. McLachlan, A. Nelson, G. McCaughan, M. Gleeson, and F. Akhlaghi Population pharmacokinetic estimation of tacrolimus apparent clearance in adult liver transplant recipients Ther. Drug Monit. 27 2005 422 430 (Pubitemid 41098815)
49. G.M. Zhang, L. Li, W.Q. Chen, S.S. Bi, X. Liu, X.L. Zhang, and W. Lu Population pharmacokinetics of tacrolimus in Chinese renal transplant patients Yao Xue Xue Bao 43 2008 695 701
50. W. Zhao, V. Elie, G. Roussey, K. Brochard, P. Niaudet, V. Leroy, C. Loirat, P. Cochat, S. Cloarec, J.L. Andre, F. Garaix, A. Bensman, M. Fakhoury, and E. Jacqz-Aigrain Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients Clin. Pharmacol. Ther. 86 2009 609 618